长风药业：ICF004完成I期临床首例健康志愿者入组给药

南方财经网09-21 22:59

南财智讯9月21日电，长风药业（02652.HK）发布自愿公告，公司研发的用于治疗间质性肺疾病（ILD）的吸入粉雾剂ICF004（化学药品第1类）I期临床试验已完成首名健康受试者的入组与给药工作，标志着该品种正式进入受试者给药阶段。ICF004采用吸入给药方式，旨在提高肺部局部药物暴露并降低全身药物暴露。前期研究者发起的临床研究（IIT）显示，在已评估剂量范围内受试者整体可耐受，未报告严重不良事件...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2669164851?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-21 22:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2669164851","market":"hk","top_or_hot":-1,"title":"长风药业：ICF004完成I期临床首例健康志愿者入组给药","media":"南方财经网","content":"<div>\n<p>南财智讯9月21日电，长风药业（02652.HK）发布自愿公告，公司研发的用于治疗间质性肺疾病（ILD）的吸入粉雾剂ICF004（化学药品第1类）I期临床试验已完成首名健康受试者的入组与给药工作，标志着该品种正式进入受试者给药阶段。ICF004采用吸入给药方式，旨在提高肺部局部药物暴露并降低全身药物暴露。前期研究者发起的临床研究（IIT）显示，在已评估剂量范围内受试者整体可耐受，未报告严重不良事件...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202609213880355870.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>长风药业：ICF004完成I期临床首例健康志愿者入组给药</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n长风药业：ICF004完成I期临床首例健康志愿者入组给药\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-09-21 22:59 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202609213880355870.html><strong>南方财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>南财智讯9月21日电，长风药业（02652.HK）发布自愿公告，公司研发的用于治疗间质性肺疾病（ILD）的吸入粉雾剂ICF004（化学药品第1类）I期临床试验已完成首名健康受试者的入组与给药工作，标志着该品种正式进入受试者给药阶段。ICF004采用吸入给药方式，旨在提高肺部局部药物暴露并降低全身药物暴露。前期研究者发起的临床研究（IIT）显示，在已评估剂量范围内受试者整体可耐受，未报告严重不良事件...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202609213880355870.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02652","symbol_name":"长风药业","start_time":0,"source_url":"http://finance.eastmoney.com/a/202609213880355870.html","article_id":"2669164851","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609213880355870.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2669164851","pubTimestamp":1790002740,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"南财智讯9月21日电，长风药业（02652.HK）发布自愿公告，公司研发的用于治疗间质性肺疾病（ILD）的吸入粉雾剂ICF004（化学药品第1类）I期临床试验已完成首名健康受试者的入组与给药工作，标志着该品种正式进入受试者给药阶段。ICF004采用吸入给药方式，旨在提高肺部局部药物暴露并降低全身药物暴露。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02652":"长风药业","BK1191":"制药"},"translate_title":"Changfeng Pharmaceutical: ICF004 completes the enrollment and administration of the first healthy volunteer in Phase I clinical trials.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02652":1.5},"content_text":"南财智讯9月21日电，长风药业（02652.HK）发布自愿公告，公司研发的用于治疗间质性肺疾病（ILD）的吸入粉雾剂ICF004（化学药品第1类）I期临床试验已完成首名健康受试者的入组与给药工作，标志着该品种正式进入受试者给药阶段。ICF004采用吸入给药方式，旨在提高肺部局部药物暴露并降低全身药物暴露。前期研究者发起的临床研究（IIT）显示，在已评估剂量范围内受试者整体可耐受，未报告严重不良事件；剂型优化后的患者药代动力学及安全性初步观察结果与研发预期基本一致。本次I期临床试验正按计划推进，旨在评估ICF004在中国健康受试者中单次及多次吸入给药的安全性、耐受性及药代动力学特征。公司提示，医药产品研发及商业化存在重大风险及不确定性，不保证后续临床结果、上市批准或商业化成功。（文章来源：南方财经网）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2669164851","isCrawlerRequest":true}